← All trials
NCT02972450
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2017
- Primary completion
- Jul 1, 2018
- Completion date
- Jul 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 170
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- French National Agency for Research on AIDS and Viral HepatitisLead sponsor
- University of WashingtonCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceStudy director
- Medical Research CouncilCollaborator
- University of HamburgCollaborator
- University of LondonCollaborator
- European CommissionCollaborator
- FIT Biotech Ltd.Collaborator
- Istituto Nazionale Malattie Infettive Lazaro SpallanzaniCollaborator
- Government of SwitzerlandCollaborator
- University of LausanneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.